3,476 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,476 shares of the life sciences company's stock, valued at approximately $276,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Fourth Dimension Wealth LLC purchased a new position in Illumina in the 4th quarter worth approximately $40,000. Assetmark Inc. boosted its stake in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after buying an additional 296 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of Illumina during the 4th quarter valued at approximately $48,000. Rakuten Securities Inc. boosted its stake in shares of Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after buying an additional 270 shares during the last quarter. Finally, Center for Financial Planning Inc. purchased a new position in shares of Illumina during the 1st quarter valued at approximately $33,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Price Performance

NASDAQ:ILMN opened at $100.05 on Friday. The business's 50-day moving average price is $86.75 and its 200 day moving average price is $96.72. The firm has a market cap of $15.84 billion, a P/E ratio of -16.48, a PEG ratio of 1.91 and a beta of 1.36. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period in the previous year, the company earned $0.98 earnings per share. Illumina's revenue was down 1.4% compared to the same quarter last year. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, CFO Ankur Dhingra purchased 6,100 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was acquired at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the transaction, the chief financial officer directly owned 24,906 shares of the company's stock, valued at $2,022,616.26. This trade represents a 32.44% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Guggenheim reduced their target price on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research note on Friday, May 9th. JPMorgan Chase & Co. reduced their target price on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Canaccord Genuity Group raised their price objective on Illumina from $87.00 to $99.00 and gave the stock a "hold" rating in a research note on Wednesday, June 11th. Piper Sandler reduced their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. Finally, Barclays restated an "underweight" rating and set a $85.00 price objective (up from $77.00) on shares of Illumina in a research note on Tuesday, June 24th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $127.16.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.